Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial von Guo, J., Carvajal, R.D., Dummer, R., Hauschild, A., Daud, A., Bastian, B.C., Markovic, S.N., Queirolo, P., Arance, A., Berking, C., Camargo, V., Herchenhorn, D., Petrella, T.M., Schadendorf, D., Sharfman, W., Testori, A., Novick, S., Hertle, S., Nourry, C., Chen, Q., Hodi, F.S.

Volltext

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response von Stein, J.E., Soni, A., Danilova, L., Cottrell, T.R., Gajewski, T.F., Hodi, F.S., Bhatia, S., Urba, W.J., Sharfman, W.H., Wind-Rotolo, M., Edwards, R., Lipson, E.J., Taube, J.M.

Volltext

BRAF -V600 Mutational Status is a Significant Associate of Brain Metastases Recurrence in Patients With Melanoma: A Retrospective Study von Maxwell, R, Ye, X, Bettegowda, C, Sharfman, W, Redmond, K.J, Kleinberg, L.R, Lim, M

Volltext

Imaging and Clinical Profile Following Concurrent Stereotactic Radiation and Immune Therapy for Melanoma Brain Metastases: Preliminary Results von Shen, C, Lin, D.D.M, Redmond, K.J, Link, K, Kummerlowe, M, Douglass, J, Lipson, E.J, Sharfman, W, Bettegowda, C, Lim, M, Kleinberg, L.R

Volltext

22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma von Nghiem, P, Bhatia, S, Daud, A, Friedlander, P, Kluger, H, Kohrt, H, Kudchadkar, R, Lipson, E, Lundgren, L, Margolin, K, Reddy, S, Shantha, E, Sharfman, W, Sharon, E, Thompson, J, Topalian, S, Cheever, M

Volltext

The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies von J W Smith, 2nd, W J Urba, B D Curti, L J Elwood, R G Steis, J E Janik, W H Sharfman, L L Miller, R G Fenton, K C Conlon

Volltext

The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin von Smith, John W, Longo, Dan L, Alvord, W. Gregory, Janik, John E, Sharfman, William H, Gause, Barry L, Curti, Brendan D, Creekmore, Stephen P, Holmlund, Jon T, Fenton, Robert G, Sznol, Mario, Miller, Langdon L, Shimizu, Masanao, Oppenheim, Joost J, Fiem, Shelby J, Hursey, Jean C, Powers, Gerry C, Urba, Walter J

Volltext

Conditioned Immune Response to Interferon-γ in Humans von Longo, D.L., Duffey, P.L., Kopp, W.C., Heyes, M.P., Alvord, W.G., Sharfman, W.H., Schmidt, P.J., Rubinow, D.R., Rosenstein, D.L.

Volltext

A phase II study of bortezomib in the treatment of metastatic malignant melanoma von Markovic, Svetomir N., Geyer, Susan M., Dawkins, Fitzroy, Sharfman, William, Albertini, Mark, Maples, William, Fracasso, Paula M., Fitch, Tom, LoRusso, Patricia, Adjei, Alex A., Erlichman, Charles

Volltext

LBA62Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358 von Naumann, R W, Oaknin, A, Meyer, T, Lopez-Picazo, J M, Lao, C, Bang, Y-J, Boni, V, Sharfman, W H, Park, J C, Devriese, L A, Harano, K, Chung, C H, Topalian, S L, Zaki, K, Chen, T, Gu, J, Li, B, Barrows, A, Horvath, A, Moore, K N

Volltext

Safety of reduced infusion times for nivolumab plus ipilimumab (N + I) and nivolumab alone (N) in advanced melanoma von Martin-Algarra, S., Haanen, J.B., Horak, C., Bhatia, S., Ribas, A., Hwu, W.-J., Slingluff, C.L., Sharfman, W.H., Callahan, M., Hodi, F.S., Wolchok, J.D., Luke, J., Young, T.C., Qureshi, A., Urba, W.J.

Volltext

Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced ref... von Segal, N.H., Infante, J.R., Sanborn, R.E., Gibney, G.T., Lawrence, D.P., Rizvi, N., Leidner, R., Gajewski, T.F., Bertino, E., Sharfman, W.H., Cooley, S., Topalian, S.L., Urba, W.J., Wolchok, J.D., Gu, X., Passey, C., McDonald, D., Aanur, P., Srivastava, S., Hodi, F.S.

Volltext

Mental neuropathy (numb chin syndrome). A harbinger of tumor progression or relapse von Burt, Richard K., Sharfman, William H., Karp, Barbara I., Wilson, Wyndham H.

Volltext

Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors von Fecher, Leslie A, Sharfman, William H

Volltext

Phase II Trial of Interleukin 1α and Indomethacin in Treatment of Metastatic Melanoma von Janik, John E., Miller, Langdon L., Longo, Dan L., Powers, Geraldine C., Urba, Walter J., Kopp, William C., Gause, Barry L., Curti, Brendan D., Fenton, Robert G., Oppenheim, Joost J., Conlon, Kevin C., Holmlund, Jon T., Sznol, Mario, Sharfman, William H., Steis, Ronald G., Creekmore, Stephen P., Alvord, W. Gregory, Beauchamp, Ann E., Smith, John W.

Volltext

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer von GAUSE, B. L, SZNOL, M, HOLMLUND, J, CONLON, K. C, VANDERMOLEN, L. A, LONGO, D. L, KOPP, W. C, JANIK, J. E, SMITH, J. W, STEIS, R. G, URBA, W. J, SHARFMAN, W, FENTON, R. G, CREEKMORE, S. P

Volltext

Major pathologic response on biopsy (MPR bx ) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response von Stein, J E, Soni, A, Danilova, L, Cottrell, T R, Gajewski, T F, Hodi, F S, Bhatia, S, Urba, W J, Sharfman, W H, Wind-Rotolo, M, Edwards, R, Lipson, E J, Taube, J M

Volltext

Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors von Janik, John E., Sharfman, William H., Smitht, John W., Longo, Dan L., Sznol, Mario, Urba, Walter J., Figlin, Robert, Pierce, William C., Bukowski, Ronald M., Fyfe, Gwen, Belldegrun, Arie

Volltext

Dose-related immunologic effects of levamisole in patients with cancer von J Janik, W C Kopp, J W Smith, 2nd, D L Longo, W G Alvord, W H Sharfman, R G Fenton, M Sznol, R G Steis, S P Creekmore

Volltext

Has the analgesic efficacy of neurolytic celiac plexus block been demonstrated in pancreatic cancer pain? von Sharfman, William H., Walsh, T.Declan

Volltext